Peruzzotti-Jametti, L. http://orcid.org/0000-0002-9396-5607
Willis, C. M.
Krzak, G.
Hamel, R. http://orcid.org/0000-0003-0013-6226
Pirvan, L.
Ionescu, R.-B. http://orcid.org/0000-0002-4488-5467
Reisz, J. A.
Prag, H. A. http://orcid.org/0000-0002-4753-8567
Garcia-Segura, M. E.
Wu, V.
Xiang, Y.
Barlas, B.
Casey, A. M. http://orcid.org/0000-0002-7242-3251
van den Bosch, A. M. R.
Nicaise, A. M. http://orcid.org/0000-0001-7160-5988
Roth, L.
Bates, G. R.
Huang, H.
Prasad, P. http://orcid.org/0009-0005-7446-0151
Vincent, A. E.
Frezza, C. http://orcid.org/0000-0002-3293-7397
Viscomi, C. http://orcid.org/0000-0001-6050-0566
Balmus, G. http://orcid.org/0000-0003-2872-4468
Takats, Z. http://orcid.org/0000-0002-0795-3467
Marioni, J. C. http://orcid.org/0000-0001-9092-0852
D’Alessandro, A. http://orcid.org/0000-0002-2258-6490
Murphy, M. P. http://orcid.org/0000-0003-1115-9618
Mohorianu, I. http://orcid.org/0000-0003-4863-761X
Pluchino, S. http://orcid.org/0000-0002-6267-9472
Article History
Received: 3 October 2022
Accepted: 6 February 2024
First Online: 13 March 2024
Competing interests
: S.P. is founder, chief scientific officer and shareholder (>5%) of CITC and chair of the scientific advisory board at ReNeuron. M.P.M. holds a patent for the use of malonate esters to decrease RET in therapeutic situations. Although unrelated to the contents of this Article, A.D. is a founder of Omix Technologies, a founder of Altis Biosciences, a scientific advisory board member for Hemanext and Forma, and a consultant for Rubius. M.P.M. is a founder of Camoxis Therapeutics and a scientific advisory board member for MitoQ. The other authors declare no competing interests.